logo

Sage Therapeutics, Inc. (SAGE)



Trade SAGE now with
  Date
  Headline
6/1/2022 6:36:06 AM Sage Therapeutics And Biogen Announce Phase 3 SKYLARK Study Of Zuranolone In Postpartum Depression Meets Endpoints
5/3/2022 6:36:48 AM Sage Therapeutics Q1 Net Loss $122.1 Mln Vs Net Loss $95.8 Mln Last Year
5/2/2022 6:36:06 AM Sage Therapeutics, Biogen Begin Rolling Submission Of NDA To US FDA For Zuranolone For Potential Treatment Of MDD
4/1/2022 6:34:57 AM Sage Therapeutics Announces Presentation Of Promising Results From The Phase 2 LUMINARY Study Of SAGE-718
3/15/2022 6:38:06 AM Sage Therapeutics Presents Encouraging Results From Phase 2 PARADIGM Study (PartA) Of SAGE-718
2/16/2022 7:10:52 AM Sage Therapeutics : Phase 3 CORAL Study Meets Primary And Key Secondary Endpoints On Major Depressive Disorder
12/8/2021 6:38:35 AM Sage : Data From Clinical Program Further Shows Efficacy & Safety Profile Of Zuranolone For Treatment Of MDD
12/1/2021 6:38:44 AM Sage Therapeutics Announce Positive, One-Year Zuranolone 50 Mg Data On Major Depressive Disorder
11/2/2021 6:56:43 AM Sage Therapeutics Q3 Net Loss $130.2 Mln Vs Net Loss $105.7 Mln Last Year
10/19/2021 6:35:26 AM Sage Therapeutics, Biogen Plan To Submit NDA For Zuranolone To FDA In H2 Of 2022
10/4/2021 6:39:02 AM Sage Therapeutics, Biogen Announce New Data From LANDSCAPE And NEST Clinical Development Programs
10/1/2021 6:35:32 AM Sage Therapeutics Announces Launch Of SageCitizen - A Social Impact Initiative
9/21/2021 6:36:32 AM Sage Therapeutics Appoints Chris Benecchi As Chief Commercial Officer
9/15/2021 6:36:04 AM Sage Therapeutics Gets Fast Track Designation For SAGE-718 For Huntington's Disease